Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Direct-acting antivirals: the endgame for hepatitis C?

Current opinion in virology - 1 Jun 2017

D'Ambrosio Roberta, Degasperi Elisabetta, Colombo Massimo, Aghemo Alessio

Abstract excerpt

Directly-acting antivirals (DAA) have finally allowed all patients to be potentially cured from chronic hepatitis C (HCV) infection. All-oral, Interferon (IFN)-free regimens are based upon the combination of molecules targeting different sites of the HCV replication process. Three classes of DAA exist: protease inhibitors (anti-NS3/4A), RNA-dependent polymerase inhibitors (anti-NS5B) and anti-NS5A inhibitors,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferons

Share to Liver Cirrhosis

Share to Protease Inhibitors

Share to Ribavirin

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 28419938
DOI: 10.1016/j.coviro.2017.03.017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Direct-acting antivirals: the endgame for hepatitis C?PMID 28419938Read ↗

Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues.Semantic proximity Read ↗

Current therapy for chronic hepatitis C: The role of direct-acting antivirals.Semantic proximity Read ↗

The hepatitis C revolution part 1: antiviral treatment options.Semantic proximity Read ↗

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Semantic proximity Read ↗

What does the pharmacological future of treating chronic hepatitis C look like?Semantic proximity Read ↗

Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.Semantic proximity Read ↗

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.Semantic proximity Read ↗

Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.Semantic proximity Read ↗

New hepatitis C therapies: the toolbox, strategies, and challenges.Semantic proximity Read ↗

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.Semantic proximity Read ↗

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.